BrainsWay Ltd - רווח נקי למניה בארבעת הרבעונים האחרונים BWAY

BrainsWay Ltd. (BWAY) management is effectively scaling sales in the US by ensuring transparency of clinical trial data. This EPS (TTM) chart for the year shows a value of 52.20, which correlates with the development of non-invasive methods for treating OCD and depression. However, chip supply chain disruptions and geopolitical tensions in several regions create risks for the timely production of brain stimulators.
BrainsWay Ltd. - פילוחים אנליטיים ומדדי מפתח (BWAY)

Use earnings per share (EPS) growth rates to evaluate business efficiency. This indicator captures the rolling annual change in net yield, reflecting the company's ability to maintain margins amid inflation. By analyzing the EPS YoY TTM percentage trend, an investor can discern the real speed of capital scaling. For BrainsWay Ltd. (BWAY), this growth confirms the commercial value of its Deep TMS patents and the resilience of demand for its unique stimulation systems.